BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
$0.62-1.44%
报价 2026-11-09
市值
$25.4M
EV
$30.6M
PE (TTM)
–
预期 PE (FY2026)
0.3x
52 周区间距高点 -73.7%
$0.43$2.35
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BYSIBeyondSpring Inc. | $25.4M | -1.4% | +41.1% | 0% | – | – | – | |
| CAMPCAMP4 Therapeutics Corporation | $294.3M | +15.5% | +63.9% | 84.8% | – | – | – | |
| DTILPrecision BioSciences, Inc. | $267.2M | -8.7% | +125.3% | 98.7% | – | – | – | |
| ALXOALX Oncology Holdings Inc. | $177.7M | +11.3% | +666.7% | 0% | – | – | – | |
| UNCYUnicycive Therapeutics, Inc. | $101.4M | +4.2% | +3460.0% | 0% | – | – | – | |
| HYFTMindWalk Holdings Corp. | $50.9M | +1.9% | – | 60.8% | – | – | – | |
| BMEABiomea Fusion, Inc. | $43M | +5.0% | +20.0% | 0% | – | – | – | |
| ATYRaTyr Pharma, Inc. | $18.6M | +19.4% | +3800.0% | 0% | – | – | – | |
| GUTSFractyl Health, Inc. Common Stock | $11.9M | -3.5% | +153.1% | 0% | – | – | – | |
| 同行中位数 | – | – | +153.1% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。